share_log

Mizuho Downgrades Revance Therapeutics to Neutral, Lowers Price Target to $9

Benzinga ·  Jan 29 20:28

Mizuho analyst Vamil Divan downgrades Revance Therapeutics (NASDAQ:RVNC) from Buy to Neutral and lowers the price target from $16 to $9.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment